Phenylazole compounds production process and antioxidants
    3.
    发明申请
    Phenylazole compounds production process and antioxidants 失效
    苯唑化合物生产工艺及抗氧化剂

    公开(公告)号:US20060247228A1

    公开(公告)日:2006-11-02

    申请号:US10566820

    申请日:2004-07-30

    摘要: The present invention is directed to compounds represented by the formula (1): B-D-Z  (1) [wherein B represent the following formula (B-1), (B-2) or (B-3); A represents an optionally substituted imidazole or pyrazole group; E represents the following formula (1a): X represents an oxygen atom, the formula: SOu, or the formula: N—R9; Y represents a carbon atom or a nitrogen atom; D represents an oxygen atom, a sulfur atom or the formula (1a); Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR10 or OR11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.

    摘要翻译: 本发明涉及由式(1)表示的化合物:<?in-line-formula description =“In-line formula”end =“lead”?> BDZ(1)<?in-line-formula description = “其中,B表示下述式(B-1),(B-2)或(B-3)表示的化合物。 A表示任选取代的咪唑或吡唑基; E表示下式(1a):X表示氧原子,式:SOu,或下式:N-R 9; Y表示碳原子或氮原子; D表示氧原子,硫原子或式(1a); Z表示(苯并二氢吡喃-2-基,苯并二氢吡喃-4-基,2,3-二氢苯并呋喃-2-基,2,3-二氢苯并呋喃-3-基等),其被 NHR 10或OR 11)]或其药学上可接受的盐,以及抗氧化剂,肾脏疾病或脑血管障碍的治疗剂和视网膜氧化损伤抑制剂,其包括化合物 作为活性成分。

    Thienopyrimidine compounds and salts thereof and process for the preparation of the same
    4.
    发明授权
    Thienopyrimidine compounds and salts thereof and process for the preparation of the same 失效
    噻吩并嘧啶化合物及其盐及其制备方法

    公开(公告)号:US06482948B1

    公开(公告)日:2002-11-19

    申请号:US09914825

    申请日:2001-08-31

    IPC分类号: C07D40914

    CPC分类号: C07D495/04 C07D495/14

    摘要: Thieno[2,3-d]pyrimidine compounds of general formula (1) useful as drugs having a cGMP-specific phosphodiesterase inhibiting effect and the preparation thereof wherein Q is formula: (CH2)n—N(r1)—C(r2) (r3), CH═CH—CH═CH, or (CH2)m which is bonded to a and b; R1 is hydrogen or C1-C6 alkyl; R2 is C3-C8 cycloalkyl optionally substituted with G1, phenyl optionally substituted with G2, or a saturated or unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, O and S and being optionally substituted with G3; and R3 is a saturated or unsaturated heretocyclic group having 1 to 4 heteroatoms selected from N, O and S and being optionally substituted with G3 or (CH2)kC(═O)R4 or CH═CHC(O)R4.

    摘要翻译: 可用作具有cGMP特异性磷酸二酯酶抑制作用的药物的通式(1)噻吩并[2,3-d]嘧啶化合物及其制备方法其中Q为式:(CH2)nN(r1)-C(r2)(r3) ),CH = CH-CH = CH或(CH2)m,其键合到a和b; R1是氢或C1-C6烷基; R2是任选被G 1取代的C 3 -C 8环烷基,任选被G 2取代的苯基,或具有1-4个选自N,O和S的杂原子并且被G3取代的饱和或不饱和杂环基; 并且R 3是具有1至4个选自N,O和S的杂原子并且任选地被G3或(CH 2)k C(= O)R 4或CH = CHC(O)R 4取代的饱和或不饱和的本体基团。